TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32613715

Group type: EXPERIMENTAL
Intervention: Infrared beak trimming (IRBT)
Number of subjects: 648

Group type: COMPARATOR
Intervention: No trimming (NBT)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Hot-blade beak trimming (HBBT)
Number of subjects: 648
Study: 35994126

Group type: EXPERIMENTAL
Intervention: MCAT + CM (collagen matrix)
Number of subjects: 16

Group type: COMPARATOR
Intervention: MCAT + CTG (connective tissue graft)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MCAT + CM and CTG (both groups)
Number of subjects: 16
Study: 33729674

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Mothers infected with Trichuris trichiura
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Moderate-and-heavy intensity infection
Number of subjects: 216
Study: 33077475

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (2 mg monthly for 6 months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Untreated fellow eyes (control group)
Number of subjects: 38
Study: 35403296

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400 IU per day) for 90 days
Number of subjects: 178

Group type: COMPARATOR
Intervention: Regular treatment (T2DM group)
Number of subjects: 178
Study: 32977846

Group type: EXPERIMENTAL
Intervention: Dual and triplex infections of HIV, Hepatitis B and C viruses among pregnant women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing for HIV, HBV or HCV infection at birth and 6 weeks using PCR technique
Number of subjects: 0
Study: 35411402

Group type: EXPERIMENTAL
Intervention: Remote antibiotic stewardship program (ASP)
Number of subjects: 9277
Study: 33989812

Group type: EXPERIMENTAL
Intervention: Nebulized low molecular weight heparin (1 mg/kg) with albuterol (2.5 mg) every 20 min for 10 min
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group received nebulized albuterol with the same dose
Number of subjects: 70
Study: 32726364

Group type: COMPARATOR
Intervention: Traditional resistance training (TRAD)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Augmented eccentric loading (AEL)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Augmented eccentric loading with athletes (AEL-ATH)
Number of subjects: 17
Study: 33843831

Group type: EXPERIMENTAL
Intervention: 14-Fr percutaneous catheters (PCs)
Number of subjects: 119

Group type: COMPARATOR
Intervention: 28-32 Fr chest tubes
Number of subjects: 119
Study: 32183861

Group type: EXPERIMENTAL
Intervention: Various intravenous iron preparations
Number of subjects: 40
Study: 33784989

Group type: EXPERIMENTAL
Intervention: Dienogest 2 mg/d for 3 months
Number of subjects: 134

Group type: COMPARATOR
Intervention: Gonadotropin‐releasing hormone agonist (GnRHa) for 3 months
Number of subjects: 134
Study: 32000598

Group type: EXPERIMENTAL
Intervention: 1 ml of low‐molecular weight Hyaluronic Acid (HA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1 ml of 10mg/ml triamcinolone acetate (CS)
Number of subjects: 50
Study: 34500117

Group type: EXPERIMENTAL
Intervention: Expert-annotated images (group 2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Computerized-morphometry-enriched images (group 3)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Raw images (group 1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall accuracy for cirrhosis diagnosis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall accuracy for fibrosis staging
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Marked fibrosis (F?3 or cirrhosis)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Discrimination between all F stages in group 2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Negative predictive value for marked fibrosis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Positive predictive value for marked fibrosis
Number of subjects: 10
Study: 32680462

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 43
Study: 33511883

Group type: EXPERIMENTAL
Intervention: β-cryptoxanthin
Number of subjects: 235

Group type: COMPARATOR
Intervention: None of the carotenoids or retinol
Number of subjects: 235
Study: 33094346

Group type: EXPERIMENTAL
Intervention: Documentation of pulmonary nodule characteristics
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Concordance with a thoracic radiologist
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Follow-up recommendations
Number of subjects: 300
Study: 34250947

Group type: EXPERIMENTAL
Intervention: Active stimulation with Transcranial Rotating Permanent Magnet Stimulator (TRPMS)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 6
Study: 33875557

Group type: EXPERIMENTAL
Intervention: Hemicraniectomy after ischemic infarction
Number of subjects: 140
Study: 35122992

Group type: EXPERIMENTAL
Intervention: Trans-resveratrol supplementation (500 mg/day for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (500 mg wheat flour for 4 weeks)
Number of subjects: 20
Study: 34642366

Group type: EXPERIMENTAL
Intervention: High dose intermittent radiation treatment (iRT, [Formula: see text] Gy [Formula: see text] 1 every 6 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: High dose hypofractionated stereotactic radiotherapy (HFSRT, [Formula: see text] Gy [Formula: see text] 5 in daily fractions)
Number of subjects: 16
Study: 33549029

Group type: EXPERIMENTAL
Intervention: Argatroban 0.5 mg/mL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) 1,000 U/mL
Number of subjects: 60
Study: 35778355

Group type: EXPERIMENTAL
Intervention: Gamification-based educational intervention (Escape Room, 2 hours)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Traditional educational programme (1.5 hours session)
Number of subjects: 302
Study: 34522625

Group type: EXPERIMENTAL
Intervention: Digital Brief Intervention (BI)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Face-to-face Brief Intervention (BI)
Number of subjects: 320
Study: 32683565

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day, 3/1 schedule) plus letrozole (2.5 mg/day, continuous)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Letrozole alone (2.5 mg/day, continuous)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 165

Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 165
Study: 35289096

Group type: EXPERIMENTAL
Intervention: Good communication with good treatment outcome
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Good communication with poor treatment outcome
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Poor communication with good treatment outcome
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Poor communication with poor treatment outcome
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Affect-based trust
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Cognition-based trust
Number of subjects: 316
Study: 33197808

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 100

Group type: COMPARATOR
Intervention: Parecoxib
Number of subjects: 100
Study: 35856373

Group type: EXPERIMENTAL
Intervention: AS-600 (600 mg of NAC + 80 mg of propolis)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: AS-1,200 (1,200 mg of NAC + 160 mg of propolis)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 34021353

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Regular Control Group (RCG)
Number of subjects: 69
Study: 34986286

Group type: EXPERIMENTAL
Intervention: Three rounds of mass administration of azithromycin (59,852 doses administered)
Number of subjects: 56376

Group type: COMPARATOR
Intervention: One round of mass administration of azithromycin followed by two rounds of targeted treatment (24,848 doses administered)
Number of subjects: 56376

Group type: EXPERIMENTAL
Intervention: Three rounds of mass administration of azithromycin (experimental group)
Number of subjects: 56376

Group type: COMPARATOR
Intervention: One round of mass administration of azithromycin followed by two rounds of targeted treatment (control group)
Number of subjects: 56376
Study: 33484699

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 32169390

Group type: EXPERIMENTAL
Intervention: Fully liquid formulation of trivalent GBS vaccine
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Lyophilized formulation of trivalent GBS vaccine
Number of subjects: 1050
Study: 36067151

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 68
Study: 33377183

Group type: EXPERIMENTAL
Intervention: Non-sedation
Number of subjects: 344

Group type: COMPARATOR
Intervention: Sedation
Number of subjects: 344
Study: 35642305

Group type: EXPERIMENTAL
Intervention: CPT + IPC
Number of subjects: 43

Group type: COMPARATOR
Intervention: KT
Number of subjects: 43
Study: 35791018

Group type: EXPERIMENTAL
Intervention: Flat, flexible school footwear
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional school footwear
Number of subjects: 24
Study: 33621632

Group type: EXPERIMENTAL
Intervention: iCBT intervention plus smartwatch app
Number of subjects: 70

Group type: COMPARATOR
Intervention: iCBT intervention alone
Number of subjects: 70
Study: 32925754

Group type: EXPERIMENTAL
Intervention: Baduanjin intervention, at least 3 to 5 times a week for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine lifestyle intervention (Control)
Number of subjects: 80
Study: 35822221

Group type: EXPERIMENTAL
Intervention: Wayfinding aids (colored doors, shapes on the floor, and signage)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Wayfinding scripts (control group)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Wayfinding aids
Number of subjects: 9
Study: 33430608

Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive interventions delivered via mobile health technologies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microrandomized trial design
Number of subjects: 0
Study: 35246202

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g intravenously every 12 h for 3 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 120
Study: 33428224

Group type: EXPERIMENTAL
Intervention: Motivational social support (MSS) from a nurse
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: MSS from a nurse plus significant other support (SOS)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 225
Study: 34663491

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1-g loading dose over 10 minutes, then a 3-g maintenance dose over 24 hours)
Number of subjects: 12009

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12009

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 12009
Study: 32961041

Group type: EXPERIMENTAL
Intervention: Whey protein‐based nutritional formula enriched with leucine and vitamin D
Number of subjects: 140
Study: 35317983

Group type: EXPERIMENTAL
Intervention: Video group (watched educational video twice)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Simulator group (trained using virtual reality simulator)
Number of subjects: 40
Study: 34230975

Group type: EXPERIMENTAL
Intervention: Non-cultured autologous epidermal cell grafting resuspended in hyaluronic acid (ready-to-use kit)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hyaluronic acid alone (neutral comparator)
Number of subjects: 36
Study: 34704539

Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.2 g.kg‐1 body mass)
Number of subjects: 11

Group type: COMPARATOR
Intervention: PLA (sodium chloride placebo 0.2 g.kg‐1 BM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: CON (no supplementation)
Number of subjects: 11
Study: 34606495

Group type: EXPERIMENTAL
Intervention: Mailed Printed Summary
Number of subjects: 384

Group type: COMPARATOR
Intervention: No Mailed Printed Summary
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Enhanced Webpage
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Email List Invitation
Number of subjects: 384
Study: 32193660

Group type: EXPERIMENTAL
Intervention: Audio-visual-directed exercise training (DVD), thrice-weekly sessions of 15 min for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CON), continued habitual lifestyle with no physical exercise
Number of subjects: 24
Study: 35718621

Group type: EXPERIMENTAL
Intervention: Intervention H (High): targeted CPB flow 3.0 L/min/m2 and mean arterial pressure (MAP) 80 mmHg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intervention N (Normal): targeted CPB flow 2.4 L/min/m2 and MAP 65 mmHg
Number of subjects: 20
Study: 34178020

Group type: EXPERIMENTAL
Intervention: Sonas program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Reading group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 35543942

Group type: EXPERIMENTAL
Intervention: Intradermal needling combined with oral motor therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral motor therapy alone
Number of subjects: 60
Study: 32060930

Group type: EXPERIMENTAL
Intervention: Diet #1 (65% fat, 15% protein, 20% carbohydrate)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diet #2 (75% fat, 15% protein, 10% carbohydrate)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diet #3 (80% fat, 15% protein, 5% carbohydrate)
Number of subjects: 10
Study: 33711814

Group type: EXPERIMENTAL
Intervention: Body acupressure using an electrostimulation device on the Neiguan (P6) acupuncture point, performed three times a week for one month (12 sessions)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Body acupressure using an electrostimulation device on the Neiguan (P6) acupuncture point
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo group (device attached but not operated)
Number of subjects: 135
Study: 33283449

Group type: EXPERIMENTAL
Intervention: 15° reverse Trendelenburg position (15-RTP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Horizontal position (HP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 5° reverse Trendelenburg position (5-RTP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 10° reverse Trendelenburg position (10-RTP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (HP, 5-RTP, 10-RTP, 15-RTP)
Number of subjects: 120
Study: 35621864

Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg subcutaneously within 24 h and 2 weeks after PCI
Number of subjects: 102

Group type: COMPARATOR
Intervention: Pitavastatin (2 mg/day) alone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Evolocumab therapy
Number of subjects: 102
Study: 34759036

Group type: EXPERIMENTAL
Intervention: HIV self-testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32228288

Group type: EXPERIMENTAL
Intervention: Dulce Digital
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study: 36075591

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with governor vessel moxibustion, applied once daily for 3 weeks (21 treatments total).
Number of subjects: 70

Group type: COMPARATOR
Intervention: Recombinant human tumor necrosis factor receptor-antibody type II fusion protein, 25 mg subcutaneously, injected once on every Monday and Friday for 3 weeks (6 injections total).
Number of subjects: 70
Study: 33206228

Group type: EXPERIMENTAL
Intervention: Intravenous amino acids (KIDIMN)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 50
Study: 36206135

Group type: EXPERIMENTAL
Intervention: Secondary prevention/rehabilitation program with remote support (phone) in group 1
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Secondary prevention/rehabilitation program with remote support (email) in group 2
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard recommendations at discharge (control group)
Number of subjects: 135
Study: 33556040

Group type: EXPERIMENTAL
Intervention: P218 1,000 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: P218 100 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: P218 (combined 1,000 mg and 100 mg)
Number of subjects: 24
Study: 32554980

Group type: EXPERIMENTAL
Intervention: Nurse-Led Internet-Based Learning and Self-care Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36014852

Group type: EXPERIMENTAL
Intervention: Selenium and Coenzyme Q10 supplementation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 32747743

Group type: EXPERIMENTAL
Intervention: Intraarticular vancomycin powder (1 g) applied before wound closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no local vancomycin)
Number of subjects: 0
Study: 36259219

Group type: EXPERIMENTAL
Intervention: HumiGard™ surgical humidification system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no humidification)
Number of subjects: 0
Study: 32437626

Group type: EXPERIMENTAL
Intervention: 10% PVP-I and 5.0% NaF varnish applied every 3 months for 2 years
Number of subjects: 284

Group type: COMPARATOR
Intervention: 5.0% NaF varnish applied every 3 months for 2 years (control)
Number of subjects: 284
Study: 34397814

Group type: EXPERIMENTAL
Intervention: Comprehensive and systematic family participation psychological nursing
Number of subjects: 78

Group type: COMPARATOR
Intervention: General routine care
Number of subjects: 78
Study: 32217479

Group type: EXPERIMENTAL
Intervention: DMS method integrating 7 CCA-based algorithms (CCA, ITCCA, MsetCCA, L1-MCCA, FBCCA, ECCA, TRCA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: M1 and M2 methods
Number of subjects: 35
Study: 35815777

Group type: EXPERIMENTAL
Intervention: ACP Specialist program implemented by existing nursing home staff after standardized training
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 137
Study: 33764531

Group type: EXPERIMENTAL
Intervention: VR-based meditation app
Number of subjects: 18

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 18
Study: 34435305

Group type: EXPERIMENTAL
Intervention: myblu™ ENDS (exclusive use for 9 days)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: myblu™ ENDS (exclusive use for 5 additional days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Combustible cigarette use (after returning from myblu™ ENDS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Dual use of myblu™ ENDS and combustible cigarettes
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: myblu™ ENDS (overall conclusion)
Number of subjects: 72
Study: 32847423

Group type: EXPERIMENTAL
Intervention: SIBP-01 (6 mg•kg-1 intravenous dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Herceptin® (6 mg•kg-1 intravenous dose)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SIBP-01
Number of subjects: 100

Group type: COMPARATOR
Intervention: Herceptin®
Number of subjects: 100
Study: 33911059

Group type: EXPERIMENTAL
Intervention: Positive religious coping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative religious coping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spouse caregivers
Number of subjects: 0
Study: 36263703

Group type: EXPERIMENTAL
Intervention: Propolis supplementation (510 mg per day)
Number of subjects: 44
Study: 32426852

Group type: EXPERIMENTAL
Intervention: Oxytocin-augmented labor
Number of subjects: 78931
Study: 35045813

Group type: EXPERIMENTAL
Intervention: Chewing mint gum
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Virtual reality
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 93
Study: 36261050

Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA-617
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cabazitaxel
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both treatments combined
Number of subjects: 200
Study: 34618684

Group type: EXPERIMENTAL
Intervention: AMY-101 (0.1 mg/site) administered via intragingival injections on days 0, 7, and 14
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: AMY-101 (0.1 mg/site) administered via intragingival injections
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo injections administered on days 0, 7, and 14
Number of subjects: 32
Study: 32474204

Group type: EXPERIMENTAL
Intervention: System-wide multifaceted quality improvement (QI) strategy including electronic alerts, risk assessments, audits, and training.
Number of subjects: 5760

Group type: COMPARATOR
Intervention: Recommended prophylaxis alone without QI (Control group).
Number of subjects: 5760
Study: 33278081

Group type: EXPERIMENTAL
Intervention: Mendelian randomization studies
Number of subjects: 0
Study: 33025010

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index‐2010 (HEI‐2010) score
Number of subjects: 158
Study: 34743231

Group type: EXPERIMENTAL
Intervention: Bright light treatment (BLT) for 60 minutes at ≥ 10,000 lux
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham-placebo treatment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Bright light treatment (BLT)
Number of subjects: 49
Study: 34127491

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with intravenous fluid coloading and phenylephrine infusion
Number of subjects: 76
Study: 36068106

Group type: EXPERIMENTAL
Intervention: CYD-TDV dengue vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33910667

Group type: EXPERIMENTAL
Intervention: Fermented dairy (≥ 160 g/d)
Number of subjects: 104805

Group type: COMPARATOR
Intervention: Dairy consumption (overall)
Number of subjects: 104805

Group type: COMPARATOR
Intervention: Dairy consumption (specific foods)
Number of subjects: 104805
Study: 32404723

Group type: EXPERIMENTAL
Intervention: Self-care program based on modeling and role-modeling theory (5 sessions of 30-45 minutes and 4 phone counseling sessions over 2 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 54
Study: 36123079

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo saline
Number of subjects: 54